Bradykinin | CAS#58-82-2 | Endothelium-dependent vasodilator

MedKoo Cat#: 463954 | Name: Bradykinin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bradykinin is a potent endothelium-dependent vasodilator and mild diuretic, which may cause a lowering of the blood pressure. It also causes contraction of non-vascular smooth muscle in the bronchus and gut, increases vascular permeability and is also involved in the mechanism of pain.

Chemical Structure

Bradykinin

CAS#58-82-2

Theoretical Analysis

MedKoo Cat#: 463954

Name: Bradykinin

CAS#: 58-82-2

Chemical Formula: C50H73N15O11

Exact Mass: 1059.5614

Molecular Weight: 1060.23

Elemental Analysis: C, 56.64; H, 6.94; N, 19.82; O, 16.60

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Bradykinin; BK; Synthetic bradykinin;

IUPAC/Chemical Name

N/A

InChi Key

QXZGBUJJYSLZLT-FDISYFBBSA-N

InChi Code

InChI=1S/C50H73N15O11/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57)/t32-,33-,34-,35-,36-,37-,38-,39-/m0/s1

SMILES Code

N[C@H](C(N1CCC[C@H]1C(N2CCC[C@H]2C(NCC(N[C@H](C(N[C@H](C(N3CCC[C@H]3C(N[C@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)Cc4ccccc4)=O)=O)CO)=O)Cc5ccccc5)=O)=O)=O)=O)CCCNC(N)=N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,060.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Anderson JL, Knowlton KU, Muhlestein JB, Bair TL, Le VT, Horne BD. Evaluation of TReatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER-An Observational Cohort Study. J Cardiovasc Pharmacol Ther. 2021 Jan 29:1074248420987054. doi: 10.1177/1074248420987054. Epub ahead of print. PMID: 33514290. 2: García-Mejía KA, Custodio-Chablé SJ, Vázquez-Franco JE, Reyes-Maldonado E, Lezama RA. β-Amyloid Orchestrates Factor XII and Platelet Activation Leading to Endothelial Dysfunction and Abnormal Fibrinolysis in Alzheimer Disease. Alzheimer Dis Assoc Disord. 2021 Jan 27. doi: 10.1097/WAD.0000000000000420. Epub ahead of print. PMID: 33512819. 3: Germenis AE, Rijavec M, Veronez CL. Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine. Clin Rev Allergy Immunol. 2021 Jan 28. doi: 10.1007/s12016-021-08836-7. Epub ahead of print. PMID: 33507496. 4: Al-Ahmad AJ, Pervaiz I, Karamyan VT. Neurolysin substrates bradykinin, neurotensin and substance P enhance brain microvascular permeability in a human in vitro model. J Neuroendocrinol. 2021 Jan 28:e12931. doi: 10.1111/jne.12931. Epub ahead of print. PMID: 33506602. 5: Coelho-de-Souza AN, Alves-Soares R, Oliveira HD, Gomes-Vasconcelos YA, Souza PJC, Santos-Nascimento T, Oliveira KA, Diniz LRL, Guimarães-Pereira J, Leal- Cardoso JH. The essential oil of Hyptis crenata Pohl ex Benth. presents an antiedematogenic effect in mice. Braz J Med Biol Res. 2021 Jan 25;54(3):e9422. doi: 10.1590/1414-431X20209422. PMID: 33503203. 6: Barić A, Dobrivojević Radmilović M. Microglia and bradykinin cross-talk in post-stroke cognitive impairment in diabetes. Am J Physiol Cell Physiol. 2021 Jan 27. doi: 10.1152/ajpcell.00402.2020. Epub ahead of print. PMID: 33502951. 7: Gagnon M, Savard M, Jacques JF, Bkaily G, Geha S, Roucou X, Gobeil F. Potentiation of B2 receptor signaling by AltB2R, a newly identified alternative protein encoded in the human bradykinin B2 receptor gene. J Biol Chem. 2021 Jan 23:100329. doi: 10.1016/j.jbc.2021.100329. Epub ahead of print. PMID: 33497625. 8: Sato M, Takahashi M, Kario K. Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary. J Clin Hypertens (Greenwich). 2021 Jan 25. doi: 10.1111/jch.14189. Epub ahead of print. PMID: 33492725. 9: Seferovic JP, Solomon SD, Seely EW. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab. 2020 Dec 25;11:2042018820970444. doi: 10.1177/2042018820970444. PMID: 33489085; PMCID: PMC7768573. 10: Brusco I, Justino AB, Silva CR, Scussel R, Machado-de-Ávila RA, Oliveira SM. Inhibitors of angiotensin I converting enzyme potentiate fibromyalgia-like pain symptoms via kinin receptors in mice. Eur J Pharmacol. 2021 Jan 18;895:173870. doi: 10.1016/j.ejphar.2021.173870. Epub ahead of print. PMID: 33476653. 11: Mansour E, Bueno FF, de Lima-Júnior JC, Palma A, Monfort-Pires M, Bombassaro B, Araujo EP, Bernardes AF, Ulaf RG, Nunes TA, Ribeiro LC, Falcão ALE, Santos TM, Trabasso P, Dertkigil RP, Dertkigil SS, Maia RP, Benaglia T, Moretti ML, Velloso LA. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three- armed randomized controlled trial. Trials. 2021 Jan 20;22(1):71. doi: 10.1186/s13063-021-05027-9. PMID: 33472675; PMCID: PMC7816150. 12: Sobotkova M, Zachova R, Hakl R, Kuklinek P, Kralickova P, Krcmova I, Hanzlikova J, Vachova M, Bartunkova J. Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients. Int Arch Allergy Immunol. 2021 Jan 20:1-8. doi: 10.1159/000512933. Epub ahead of print. PMID: 33472202. 13: Sonkodi B. Delayed Onset Muscle Soreness (DOMS): The Repeated Bout Effect and Chemotherapy-Induced Axonopathy May Help Explain the Dying-Back Mechanism in Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. Brain Sci. 2021 Jan 15;11(1):108. doi: 10.3390/brainsci11010108. PMID: 33467407; PMCID: PMC7830646. 14: Oz M, Lorke DE. Multifunctional angiotensin converting enzyme 2, the SARS- CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomed Pharmacother. 2021 Jan 5;136:111193. doi: 10.1016/j.biopha.2020.111193. Epub ahead of print. PMID: 33461019; PMCID: PMC7836742. 15: Aztatzi-Aguilar OG, Pardo-Osorio GA, Uribe-Ramírez M, Narváez-Morales J, De Vizcaya-Ruiz A, Barbier OC. Acute kidney damage by PM2.5 exposure in a rat model. Environ Toxicol Pharmacol. 2021 Jan 15;83:103587. doi: 10.1016/j.etap.2021.103587. Epub ahead of print. PMID: 33460805. 16: Lu J, Sun PD. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. J Biol Chem. 2020 Dec 25;295(52):18579-18588. doi: 10.1074/jbc.RA120.015303. PMID: 33453855. 17: Coelho SVA, Rust NM, Vellasco L, Papa MP, Pereira ASG, Silva Palazzo MFD, Juliano MA, Costa SM, Alves AMB, Cordeiro MT, Marques ETA, Scharfstein J, Arruda LB. Contact System Activation in Plasma from Dengue Patients Might Harness Endothelial Virus Replication through the Signaling of Bradykinin Receptors. Pharmaceuticals (Basel). 2021 Jan 12;14(1):56. doi: 10.3390/ph14010056. PMID: 33445640; PMCID: PMC7827195. 18: Islam R, Maeda H, Fang J. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors. Expert Opin Drug Deliv. 2021 Jan 29:1-14. doi: 10.1080/17425247.2021.1874916. Epub ahead of print. PMID: 33430661. 19: Fijen LM, Bork K, Cohn DM. Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2. Clin Rev Allergy Immunol. 2021 Jan 9. doi: 10.1007/s12016-021-08832-x. Epub ahead of print. PMID: 33423210. 20: Souza LV, de Almeida SS, De Meneck F, Thomazini F, Araujo RC, Franco do MC. Polymorphism of the bradykinin type 2 receptor gene modulates blood pressure profile and microvascular function in prepubescent children. Peptides. 2021 Jan 4;137:170491. doi: 10.1016/j.peptides.2020.170491. Epub ahead of print. PMID: 33412234.